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Abstract
Combination therapy has become a major strategy in cancer treatment. We used anisamide-
targeted lipid–calcium–phosphate (LCP) nanoparticles to efficiently deliver HIF1α siRNA to the 
cytoplasm of sigma receptor-expressing SCC4 and SAS cells that were also subjected to 
photodynamic therapy (PDT). HIF1α siRNA nanoparticles effectively reduced HIF1α expression, 
increased cell death, and significantly inhibited cell growth following photosan-mediated 
photodynamic therapy in cultured cells. Intravenous injection of the same nanoparticles into 
human SCC4 or SAS xenografted mice likewise resulted in concentrated siRNA accumulation and 
reduced HIF1α expression in tumor tissues. When combined with photodynamic therapy, HIF1α 
siRNA nanoparticles enhanced the regression in tumor size resulting in a ~40% decrease in 
volume after 10 days. Combination therapy was found to be substantially more effective than 
either HIF1α siRNA or photodynamic therapy alone. Results from caspase-3, TUNEL, and CD31 
marker studies support this conclusion. Our results show the potential use of LCP nanoparticles for 
efficient delivery of HIF1α siRNA into tumors as part of combination therapy along with PDT in 
the treatment of oral squamous cell carcinoma.
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Introduction
Oral and pharyngeal cancer together rank sixth among the most prevalent cancers in the 
world [1]. Current treatment involves radical surgical excision, chemotherapy and 
radiotherapy, either separately or in combination. Wide excision of oral cancer can result in 
facial deformities that impair postsurgical quality of life, underscoring the need to develop 
new approaches to treatment. Photodynamic therapy (PDT) with systemic or topical 
administration of photosensitizer is considered to be a non-invasive, well-tolerated 
alternative as it can be used repeatedly without cumulative side effects, resulting in little or 
no scar formation [2–5]. This technique is based on the administration of exogenous 
photosensitizing drugs to render tumor tissue sensitive to non-thermal light of a specific 
wavelength. The sensitizers are relatively inert and have selective affinity for tumor tissues. 
In the presence of oxygen, light illumination activates the drug and in turn, through a type II 
photochemical reaction, produces singlet oxygen which kills tumor cells directly or does so 
by damage to the tumor-associated vasculature [2,6,7].
Photosan is converted intracellularly into the active photosensitizer, protoporphyrin IX 
(PpIX), in epithelial cells. PpIX is then activated by 630 nm red light to produce reactive 
oxygen. Photosanmediated PDT (topical photosan–PDT) has been demonstrated to be an 
effective treatment modality for oral pre-cancers, however, more than five treatments are 
needed for relatively large, oral precancerous lesions [8]. In an effort to enhance the 
therapeutic effect of topical photosan–PDT, we tested a novel approach using calcium 
phosphate (CaP) based nanoparticle (NP) technology to deliver encapsulated HIF1α siRNA 
to tumor cells. HIF1α is a hypoxia inducible factor and plays a pivotal role in tumorigenesis, 
especially in the regulation of apoptosis and cell cycle progression. CaP is not only 
biocompatible and biodegradable, it also binds nucleic acids with high affinity. It dissolves 
in the acidic pH of the endosome, increasing osmotic pressure resulting in rupture of the 
endosome and subsequent release of cargo into the cytoplasm. We stabilized CaP cores with 
dioleoylphosphatydic acid (DOPA) and further coated them with a cationic lipid. The final 
NP presents as a hollow spherical structure ranging from 25 to 30 nm in diameter and 
possess an asymmetric lipid bilayer at the surface. Using the ligand anisamide (AA), lipid–
calcium–phosphate (LCP) can efficiently deliver siRNA to sigma receptor-expressing tumor 
cells to stimulate a strong RNAi effect. With an interest in developing improved therapeutic 
strategies for oral cancers, we conducted experiments in both cultured cells and xenograft 
tumors in nude mice to determine if inhibition of HIF1α expression by siRNA nanoparticles 
would enhance the cell-killing efficacy of topical photosan–PDT.
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1,2 – Distearoryl – sn – glycero – 3 – phosphoethanolamine – N – [methoxy 
(polyethyleneglycol-2000) ammonium salt (DSPE-PEG2000), dioleoylphosphatidic acid 
(DOPA) and 1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) were 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). DSPE–PEG–anisamide (AA) was 
synthesized in our lab as described previously. Texas Red labeled double-stranded 
oligonucleotide (oligo), with the same siRNA sequence [9], was purchased from Integrated 
DNA Technologies (Coralville, IA). Other chemicals were obtained from Sigma-Aldrich (St. 
Louis, MO) without further purification. Human squamous cell carcinoma cells, SCC4 were 
purchased from Bioresource Collection and Research Center (BCRC; Hsinchu, Taiwan, 
ROC) and SAS was a gift from Professor Liu, Yang Ming University. Both SCC4 and SAS 
cells were derived from human tongue with expressing sigma receptors and were used as 
model cells in our study, SCC4 or SAS cells are cultured at 37°C in a humidified 5% CO2 
and 95% air incubator in DMEM/F12 medium (Invitrogen, Grand Island, NY, US) 
supplemented with 10% fetal bovine serum (Invitrogen, Grand Island, NY, US). When cells 
reached 80% confluence, the cells were removed with 0.05% trypsin–EDTA (Invitrogen) 
and were replated in DMEM/F12 medium. HIF1α siRNA (target sequence: 5′-AGA GGU 
GGA UAU GUG UGG GdTdT-3′) [9] and scrambled siRNA target sequence: 5′-AUG UAU 
UGG CCU GUA UUAG-3′) were purchased from Dharmacon (Lafayette, CO, USA) and 
Texas Redlabeled control siRNA was purchased from Dharmacon (Lafayette, CO, USA) in 
unprotected, desalted, annealed form. All sequences were adopted from published studies. 
Photosan was kindly sponsored by SeeLab (Wesselburenerkoog, Germany).
PDT light source
A portable innovative LED light source (Wonder Light, MedEx Healthcare Inc., Taoyuan, 
Taiwan) was used for PDT treatment of SCC4 xenograft nude mouse tumors. A user-friendly 
interface of this LED light source coupled with optical fiber was designed and used for the 
light treatment. The light source consists of a high-power LED, with the wavelength 
centered at 640 nm and a bandwidth of 20 nm. The power density of the Wonder Light 
system was tunable, ranging from 1 to 400 mW/cm2. The size of the light spot is 1.8 cm in 
diameter at a working distance of 1 cm. The power density was set at 320 mW/cm2 and the 
light energy dosage was 100 J/cm2 [10].
Formulation of LCP encapsulated HIF1α siRNA
LCP was prepared as described previously with slight modifications [11,12]. The target 
moiety of LCP surface is anisamide to recognize sigma receptors on the surface of SCC4 or 
SAS. Briefly, 300 μl of 2.5 M CaCl2 with 12 μg of siRNA was dispersed in a 20 ml oil phase 
(cyclohexane/Igepal CO-520 (71/29, v/v)) to form a well-dispersed water-in-oil reverse 
microemulsion. The phosphate micro-emulsion was prepared by dispersing 300 μl of 12.5 
mM Na2HPO4 in a separate 20 ml oil phase. 100 μl (20 mM) of DOPA in chloroform was 
added to the phosphate solution. After mixing the above two microemulsions for 20 min, 40 
ml of ethanol was added to the combined solution and the mixture was centrifuged. After 
three cycles of ethanol wash, the CaP core pellets were dissolved in chloroform. To prepare 
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the final LCP, 500 μl of CaP core was mixed with 75 μl of 10 mM DOTAP, 10 mM 
cholesterol, 3 mM DSPE-PEG-2000 and 3 mM DSPE–PEG–AA. After evaporating the 
chloroform, the residual lipid was hydrated in 200 μl of 5% glucose to form LCP.
Particle size and charge measurements
Particle size and zeta potential of the final LCP were measured by a Malvern NanoSizer 
series (Westborough, MA). Transmission Electron Microscope (TEM) images of LCP NP 
were acquired using TECNAI F20, Philips TEM (FEI Company, Eindhoven, The 
Netherlands).
Western blot analyses of HIF-1α and sigma receptor
Excised tumors were homogenized and lysed in the lysis buffer using PRO-PREP™ protein 
extraction solution. Samples containing an equal quantity of protein, as determined by BCA 
Protein Assay Kit (Pierce, Thermo Fisher Scientific Inc., Rockford, IL, US), were denatured 
in the sample buffer by boiling at 100 °C for 5 min. Prepared samples were resolved on a 
5%/12% Bis-Tris acrylamide gel along with molecular size markers. SDS-PAGE 
electrophoresis was carried out at a constant voltage (150 V) at room temperature. Proteins 
were electrophoretically transferred to a nitrocellulose (NC) membrane (Whatman GmbH, 
Dassel, Germany) at 4 °C at constant 300 mA for 2 h. Following the transfer, the NC blot 
was blocked with Block PRO blocking buffer (Visual Protein Biotechnology Corporation, 
Taiwan), incubated with rabbit primary antibodies against hypoxia inducible factor-1α 
(HIF-1α, 120 kDa; GenTex, Taipei, Taiwan, ROC) (1:1000 dilution), and sigma receptor 
(SIGMAR1, 25 kDa; GenTex, Taipei, Taiwan, ROC) (1:1000 dilution), respectively, 
followed by peroxidase-conjugated goat anti-rabbit IgG (GenTex) (1:10,000 dilution), and 
developed in enhanced chemiluminescence substrate (PerkinElmer, Inc., Boston, MA, 
USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; GenTex) (1:1000 dilution) 
was used as an internal control. Intensities of hybridized protein bands on western blots were 
semi-quantified by VisionWorkers LS software and blots were scanned using an imaging 
system (BioDoc-It 220, UVP®, Upland, CA, US).
In vitro cellular uptake study of targeting on sigma receptor
SCC4 or SAS cells (3 × 104 cells/well/0.5 ml) were seeded in 24-well plates 16 h before 
experimentation. Cells were treated with different formulations containing 100 nM Texas 
Red-DNA oligos in the culture medium at 37 °C for 4 h. SCC4 or SAS cells were washed 
three times with PBS followed by incubation with 300 μl lysis buffer (0.3% Triton X-100 in 
PBS) at 37 °C for 0.5 h. The fluorescence intensity of 100 μl cell lysate was determined by 
an IVIS reader (λex: 595 nm, λem: 613 nm) (IVIS Lumina II, Perkin Elmer Caliper Life 
Sciences, Hopkinton, MA). For free ligand competition study of the sigma receptor, either 
SCC4 or SAS cells were co-incubated with 50 μM haloperidol with different formulations.
In vitro cellular study of nontargeted and targeted LCP uptake
SCC4 cells (2 × 104 per well) were seeded in 6-well plates (Corning Inc., Corning, NY) with 
cover glass for 12 h before the experiment. Cells were treated with different formulations at 
a concentration of 100 nM Texas Red labeled DNA oligos in serum containing medium at 
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37 °C for 4 h. After washing twice with PBS, cells were fixed with 4% paraformaldehyde in 
PBS at room temperature for 1 hr, and then treated with 0.1% Triton X-100 in PBS for 30 
min at 37 °C, counterstained with DAPI nuclei acid stain for nuclei staining for 5 min 
(Molecular Probe, Invitrogen, Eugene, OR, USA), WGA (Wheat Germ Agglutinin 
Conjugates) for membrane staining for 10 min (Molecular Probes, Invitrogen, Eugene, OR, 
USA) and were monitored and imaged using an Eclipse C1 plus, Confocal Microscope at 
200× magnification (Nikon, Tokyo, JP).
Cell viability analysis by MTT assay
SCC4 cells (5 × 103 per well) were seeded in 24-well plates with 500 μl of DMEM-F12 
medium containing 10% fetus bovine serum per well. When SCC4 cells were cultured to 
70% confluence, cells were then treated with different formulations at a concentration of 100 
nM for HIF1α siRNA, or left untreated. After incubating the cells for 48 h, MTT assay was 
used to evaluate the cell viability. Untreated cells served as the indicator of 100% cell 
viability. The absorbance was measured at 570 nm using a microplate reader.
Establishment of SCC4 and SAS xenograft mouse models for treatments
Either 5 × 106 SCC4 or SAS cells in 200 μl of medium were injected subcutaneously in the 
lower back region of female nude mice. Tumor-bearing mice were treated for 3 days at 24 h 
interval of a total of three times for SCC4 or SAS xenograft model and certain groups of 
SCC4 bearing mouse were given 10 mg photosan/kg body weight once after siRNA was 
given. When SCC4 or SAS tumor size reached approximately 500–800 mm3, SCC4 animals 
were randomly divided into 5 groups (Table 1A). The 5 treatments of the groups were given 
by tail vein injection. The dose of LCP control or HIF1α siRNA given to SCC4 or SAS 
tumor was 0.36 mg/kg respectively [11]. PDT was given using 0.05 mg photosan dissolved 
in 200 μl PBS/25 g animal by tail vein injection. Tumor sizes were measured daily and the 
mice were sacrificed on the 11th day. SAS animals were randomly divided into 3 groups 
(Table 1B). Tumor sizes were measured daily and the mice were sacrificed on the 4th day. 
Tumor size was determined by caliper measurement. SCC4 and SAS tumors and organs 
were collected, dissected, and fixed in 10% formalin for further experiments. These studies 
were approved (Permit Number: 9915) and carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of the Institutional Animal Care and 
Use Committee of Chung Yuan Christian University, Chungli, Taoyuan, Taiwan, ROC.
qRT-PCR of HIF1α siRNA knockdown effect
On the 10th day after designed treatments of SCC4 xenograft mouse or the 3rd day after 
knockdown treatments, the mRNA levels of HIF1 1α in the SCC4 or SAS tumor tissues 
were also analyzed by using qRT-PCR. A total of 0.05 g of specimens of each group of 
either SCC4 or SAS tumor tissues were sampled and homogenated using liquid nitrogen to 
further analyze HIF1α RNA knockdown effect. Total tissue RNA was extracted with an 
RNAzol® RT (Molecular Research Center Inc., Cincinnati, Ohio, US), and individual 
cDNAs were synthesized with a RevertAid First Strand cDNA Synthesis Kit (Famantas, 
Thermo Fisher Scientific Inc., Waltham, MA, US). Realtime quantitative PCR (qPCR) was 
performed with a Universal Probe Master (Roche, Applied Science, Mannheim, Germany). 
Reactions were run with a standard cycling program: 50 °C for 2 min, 95 °C for 10 min, 40 
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cycles of 95 °C for 15 sec, and 60 °C for 1 min, on a real-time PCR system (Applied 
Biosystems, Foster City, CA, US).
Immunohistochemistry of CD31 and Ki67
CD31 and Ki67 immunohistochemistry was done on paraffin-embedded sections of SCC4 
and SAS tumor tissues. For CD31 examination, after fixation with cold acetone for 20 min, 
samples were incubated with a 1:50 dilution of rat monoclonal anti-mouse CD31 antibody 
(BD Pharmingen, San Diego, CA) at 4 °C for 1 h followed by incubation with HRP 
conjugated goat anti-rat IgG antibody (1:200, Santa Cruz Biotechnology, Santa Cruz, CA) 
for 30 min. For Ki67 examination, a heat mediated antigen retrieval step was performed 
using 10 mM citrate buffer pH 6.0. Samples were incubated with a 1:200 dilution of rabbit 
monoclonal anti-mouse Ki67 antibody (ab16667, Abcam (Cambridge, MA)) for 30 min 
followed by incubation with HRP conjugated anti-rabbit antibody (Cat.#: 4002-1, 
Epitomics) for 15 min. Visualization was achieved with a DAB detection kit (Pierce, 
Rockland, IL) using an Olympus BX53 light microscope (Olympus Corp., Tokyo, JP). 
Multiple (7 images) tumor images of CD31 or Ki67 on high power (400×) of 5 groups were 
acquired using software image for analysis.
Apoptosis analysis of cleaved caspase-3 and TUNEL
Cleaved caspase-3 immunohistochemistry and terminal deoxyribonucleotide transferase 
(TdT)-mediated nick-end labeling (TUNEL) staining was performed to detect apoptotic cells 
in SCC4 tumor tissues of 5 study groups using paraffin-embedded sections of SCC4 tumor 
tissues. After fixation with cold acetone for 20 min, samples were incubated with a 1:300 
dilution of rabbit polyclonal cleaved caspase-3 (Asp175) antibody (#9661, Cell signaling, 
Danvers, MA, US) at 4 °C for 1 h followed by incubation with HRP conjugated goat anti-
rabbit IgG antibody (1:200, Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min. 
Visualization of cleaved caspase-3 was achieved with a DAB detection kit (Pierce, 
Rockland, IL). TUNEL assay was performed in 5 study groups using an in situ cell death 
detection kit, POD, TUNEL System (Roche, Basel, Switzerland). This detection kit is based 
on the detection of single-and double-stranded DNA breaks that occur at the early stages of 
apoptosis. Cell nuclei with DAB substrate staining were defined as TUNEL-positive nuclei. 
TUNEL-positive nuclei were monitored. All specimens were examined with an Olympus 
BX53 light microscope (Olympus Corp., Tokyo, JP). Multiple (7 images) tumor images of 
cleaved caspase-3 and Tunel on high power (400×) of 5 groups were obtained using software 
image for analysis.
Toxicity assay
All toxicity was assayed and analyzed using C57BL/6JNarl mouse serum. Cytokines, 
interleukin-6 (IL-6) and IL-12, were analyzed using mouse serum after the therapeutic dose 
(0.36 mg/kg) of LCP. Levels of secreted liver biomarkers (aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), total-Bilirubin (t-Bil)), kidney biomarkers (creatinine, 
blood urea nitrogen (BUN), calcium and phosphorus), albumin, total protein, globulin, 
glucose and muscle biomarkers (lactic dehydrogenase and creatine kinase) were assayed 
using LCP HIF1α siRNA (3 times) treatment of normal C57BL/6JNarl black mice (n = 3).
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Data are presented as mean values ± SD. The statistical significance was determined by 
using one way ANOVA.
Results
Inhibition of tumor cell growth in culture
The effect of HIF1α knockdown on the viability of cultured SCC4 cells was determined by 
MTT assay (Fig. 1). A significantly diminished survival rate (p < 0.001) was seen with 
either HIF1α siRNA alone or the combination of HIF1α siRNA plus PDT when compared 
to light-only control or PDT treatment alone. Scrambled HIF1α siRNA however, did not 
significantly affect cell survival rate. Enhanced cell death was observed when HIF1α siRNA 
and PDT therapy were combined in cultured SCC4 cells (Fig. 1). These findings support the 
potential use of this combined therapy for the treatment of oral cancers and prompted further 
investigation in vivo.
Characterization of LCP
The CaP–HIF1α siRNA core was stabilized with DOPA, coated with DOTAP, further 
grafted with DSPE–PEG (non-targeted) or DSPE–PEG–AA (targeted), and then examined 
for particle size and morphology. CaP cores presented as hollow, spherical structures 20–30 
nm in diameter by TEM (Fig. 2A) with an electron transparent outer-ring composed of lipid 
bilayer. Overall particle size measured 25–30 nm by dynamic light scattering (Fig. 2B, C), 
consistent with previously reported results [11,12]. The zeta potential of LCP HIF1α siRNA 
is 45.2 ± 1.7 mV (in triplicates).
In vitro cellular uptake study
To investigate delivery efficiency of our LCP NP formulations, we performed the cellular 
uptake study using double-stranded (ds) HIF1α oligonucleotides (DNA) labeled with Texas 
Red dye (ds DNA) in SCC4 or SAS cell lines. The fluorescence intensity of the cell lysate 
represents the intracellular delivery efficiency for DNA oligonucleotides (oligos, DNA) by a 
given formulation. As shown in Fig. 3A, cell lysate from SCC4 or SAS cells treated with 
free Texas Red-HIF1α oligos showed background fluorescence. Those from SCC4 or SAS 
cells treated with LCP NP formulations with the ligand anisamide (DNA in NP) had 
significantly higher fluorescence intensities than LCP NP formulations without the ligand 
anisamide. LCP can efficiently deliver Texas Red-oligos to sigma receptor-expressing tumor 
cells in both SCC4 and SAS cell lines. Addition of free haloperidol, a known inhibitor of the 
sigma receptor, significantly reduced the delivery efficiency of LCP NP but not other 
formulations. In addition, targeted LCP NP showed 2.5-fold or 3.5-fold increased delivery 
efficiency compared to non-targeted LCP NP in the SCC4 or SAS cell line, respectively. The 
addition of free haloperidol significantly reduced the delivery efficiency of targeted LCP NP 
but no other formulations. To understand the sigma receptor of SCC4 and SAS cells, western 
blot experiments were conducted. Fig. 3B shows that sigma receptor proteins were 
expressed in both SCC4 and SAS cell lines.
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LCP in vitro cellular and in vivo animal uptake analysis
Sigma receptors are over-expressed in a variety of human tumors suggesting the potential 
use of anisamide as a ligand for delivery of genes and drugs to the surface of cancer cells. To 
investigate the use of sigma receptors for specific targeting to oral squamous cancer cell 
lines (OSCC) and tumors, we used the human SCC4 cell line and PEGylated LCP with 
anisamide (AA) on the surface. Delivery of targeted and non-targeted LCP to OSCC was 
measured by cellular uptake of double-stranded (ds) HIF1α oligonucleotides (DNA) labeled 
with Texas Red (Fig. 3). Most red fluorescence was detectable throughout the cytoplasm 40 
min after addition of AA-targeted NP (Fig. 3D). The red fluorescence in the cells treated 
with untargeted LCP NP appeared either extracellular or as punctate spots inside the cells, 
indicating the absence of cytosolic delivery of the oligonucleotides (Fig. 3C). Thus, the 
presence of the AA ligand had led to internalization and cytoplasmic cargo delivery of the 
LCP in the treated cells.
To confirm in vivo uptake, SCC4 tumor bearing nude mice were intravenously injected with 
AA-targeted Texas Red labeled LCP NP and fluorescence intensity in the tumor and organs 
was measured after 4 h (Fig. 4). Staining was barely detectable with AA-targeted Texas Red 
labeled ds DNA LCP NP in the heart, liver, spleen, lung, and kidney. However, we found the 
tumor region showed the strongest signal. Delivery of HIF1α siRNA to the tumor is 
expected to result in effective reduction in HIF1α expression.
In vivo therapeutic outcomes of combined treatment
In order to test anti-cancer therapeutic effects of reduced HIF1α expression in xenograft 
tumors, nude mice were inoculated with SCC4 or SAS OSCC cells and xenografts were 
allowed to grow to a volume of 500~800 mm3. Animals were then randomly divided into 
either three (SAS) or five treatment groups (SCC4) (Fig. 5) and treated with LCP HIF1α 
siRNA a total of 3 times at 24 h intervals and then given 2 mg/kg body weight of photosan. 
SCC4 xenograft mice were treated with (1) PBS; (2) scrambled siRNA in LCP; (3) HIF1α 
siRNA in LCP and photosan (2 mg/kg) without light delivery; (4) HIF1α siRNA in LCP and 
PBS with light delivery (100 J); (5) HIF1α siRNA in LCP and photosan (2 mg/kg) with light 
delivery (100 J), respectively. SAS xenograft mice were treated with (1) PBS; (2) scrambled 
siRNA in LCP; and (3) HIF1α siRNA in LCP, respectively. siRNA dose in all groups was 
0.36 mg/kg. Tumor size was measured daily and mice were sacrificed on day 11 (SCC4) or 
24 h after the last treatment (SAS). Targeted LCP containing HIF1α siRNA had a significant 
inhibitory effect on SCC4 tumor size with best results seen on day 7 after combined 
treatment with PDT (p < 0.01) (Fig. 5), with the degree of inhibition ranging from 40% to 
85% reduction in tumor volume by day 10 (p < 0.01) (Fig. 5). Tumors shrank in size with 
HIF1α siRNA treatment alone, but grew back quickly in the absence of subsequent PDT. 
Combined therapy thus extended the tumor reduction effect to a period of at least 7 days of 
enhanced therapeutic efficacy.
In vivo antitumor therapeutic mechanism
We quantified the degree of RNA knockdown caused by targeted LCP using qRT-PCR on 
day 10 (SCC4) and one day after treatments were given to SAS mice. HIF1α siRNA 
formulated in LCP could silence 80–90% of HIF1α mRNA expression in SCC4 (Fig. 6; p < 
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0.001; n = 4) and 60% in SAS xenografts (Fig. S1A; p < 0.05; n = 4), whereas scrambled 
siRNA showed little effect. Thus, the observed therapeutic efficacy of HIF1α siRNA 
correlated well with RNAi of the target gene. Since the specimens were collected with 
combination PDT on day 10 after treatments, the protein expression profiles may not present 
the knockdown alone effect. In Fig. S1B, western blots of HIF1α knockdown effect in SAS 
xenografts were also examined. The amount of HIF1α protein decreased compared to PBS 
group in Fig. S1B.
In vivo antitumor H&E, CD31, Ki67, caspase-3, and TUNEL assay
To determine the biological effects of treatment with LCP HIF1α siRNA, tumors were 
harvested from mice following therapy and were subjected to hematoxylin and eosin (H&E) 
staining (Fig. 7), vessel marker (CD31), cellular proliferation (Ki67) and apoptosis 
(Caspase-3, TUNEL) (Fig. 8) assays. We also performed H&E staining of the liver and 
kidney from treated mice (Fig. 7) and no organ damage was observed. Hollow zones were 
seen in treated SCC4 and SAS tumor tissues, further supporting the conclusion that 
treatment with HIF1α siRNA in targeted LCP both with and without PDT reduced tumor 
volume (Figs. 7 and S2). Additionally, LCP HIF1α siRNA induced a significant decrease in 
CD31 and Ki67 staining, increased caspase-3 staining and increased response in the TUNEL 
assay in xenograft tumor tissues (Figs. 8 and S3). Body weight did not change significantly 
during the period of treatment (data not shown). In addition, quantification of the staining 
intensity of Ki67, caspase-3 and CD31 using image J software in Figs. 8A and S3A and the 
staining intensity of such biomarkers are shown in Figs. 8B and S3B, respectively. We 
observed that the major cause of tumor shrinkage is the mechanism of apoptosis due to the 
up-regulation of caspase-3, and the downregulation of Ki67 and CD31 in the therapeutic 
groups. We have used the 2° antibody only to do the negative controls for CD31 and Ki67 
and the results in Figs. S9 and S10 showed low background.
Toxicity assay
All toxicity was assayed and analyzed using C57BL/6JNarl mouse serum. At the therapeutic 
dose (0.36 mg/kg), LCP did not induce significant levels of cytokines including 
interleukin-6 (IL-6) and IL-12 (Fig. S4). Levels of secreted liver biomarkers (aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), total-Bilirubin (t-Bil)) (Fig. S5), 
kidney biomarkers (creatinine, blood urea nitrogen (BUN), calcium and phosphorus) (Fig. 
S6), albumin, total protein, globulin, glucose (Fig. S7) and muscle biomarkers (lactic 
dehydrogenase and creatine kinase) (Fig. S8) were all statistically unchanged in the serum 
after LCP HIF1α siRNA (3 times) treatment of normal C57BL/6JNarl black mice. This was 
consistent with the lack of damage to the liver, kidneys and muscles and unchanged calcium 
or phosphorus level in serum (n = 3).
Discussion
Although progress has been made, the 5-year survival rate for OSCC has not improved 
substantially in the past 10 years. Advances in tumor biology and understanding 
mechanisms of oncogenesis have revealed several potential molecular targets for OSCC 
treatment. We show here that a novel receptor-targeted delivery system (LCP) loaded with 
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siRNA targeting the HIF1α oncogene led to potent antitumor effects in OSCC. HIF1α is a 
core transcriptional factor of oxygen-suppressed (hypoxia) genes that mediate a wide range 
of adaptive responses to changes in oxygen tension in the tumor microenvironment. The 
center of solid tumors tends to be hypoxic enough to encourage angiogenesis and 
irregularities in vasculature and blood flow, likely contributing to rapid tumor growth 
[13,14]. Inhibition of the expression of this major hypoxic transcriptional factor by HIF1α 
RNAi is predictably effective in enhancement of tumor cell-killing effects, induction of 
apoptosis, and inhibition of tumor growth as shown by the current study.
CaP-based composite NPs have been recently developed for siRNA delivery [11,15,16]. 
These nanoparticles are effective for HIF1α siRNA delivery because the CaP can efficiently 
dissolve in the low pH microenvironment of the endosome and increase the osmotic pressure 
causing the endosome to swell and burst for a more consistent release of entrapped siRNA 
into the cytoplasm [12]. LCPs, CaP coated with lipid with target moiety (AA), are of a 
relatively small size (20–30 nm), biodegradable, biocompatible and have very low 
immunogenicity and non-toxic properties making them suitable for pre-clinical and clinical 
applications. In the present study, we have utilized lipid membrane coated CaP NP, i.e., the 
LCP [15], to deliver HIF1α siRNA in mouse OSCC models. SCC4 and SAS cells expressing 
sigma receptors were used as model cells in our in vitro and in vivo studies. During LCP 
formulation, the CaP core, stabilized with anionic lipid (DOPA), was prepared by using a 
reverse microemulsion synthetic approach and further coated with cationic lipid 
(DOTAP:cholesterol = 1:1). To prolong the in vivo circulation time and improve the cellular 
uptake, the final LCP was PEGylated with DSPE–PEG–AA. The LCP particles were 25–30 
nm in diameter, which is a suitable size to be internalized by receptor-mediated endocytosis 
[17]. PEGylation on the nanoparticle surface could also maintain colloidal stability when 
redispersed after drying [18]. TEM revealed that LCPs were well dispersed with a hollow 
and spherical morphology and fairly uniform particle size (Fig. 2). Cabral et al. [19] reported 
that the enhanced delivery of drugs to tumor cells using nanoparticles mainly depends on 
size. They concluded that nanoparticles with a size smaller than 50 nm can penetrate poorly 
permeable tumors, such as pancreatic tumors. These findings support our LCP NP as 
suitable and sophisticated nanocarriers that enable efficient delivery and release of payloads 
to targeted cancer cells. Cellular uptake studies showed that the Texas Red-labeled dsDNAs 
were evenly distributed throughout the cytoplasm of SCC4 cells at 40 min post treatment 
when delivered by AA-targeted LCPs, while most untargeted LCPs remained attached to cell 
membranes without entering the cells or releasing Texas Red dye (Fig. 3). LCP-AA was able 
to successfully and efficiently deliver siRNA in a sigma receptor-mediated process (Fig. 3). 
IV injection of Texas Red-labeled HIF1α dsDNA formulated in LCPs led to preferential 
accumulation of the labeled dsDNA (3~5 fold increase in fluorescence intensity) throughout 
the cytoplasm of the whole tumor relative to major organs (Fig. 4), possibly because of 
higher passive transport of densely PEGylated lipid nanoparticles to leaky vessels of the 
tumor and extended blood circulation time. Additionally, AA may facilitate internalization, 
after which the pH-sensitive CaP core can disassemble in the acidic endosome and 
efficiently release the HIF1α dsDNA into the cytoplasm. In fact, Liu et al. [20] found 
fluorescence signals in LCP NP attenuated drastically in both liver and spleen organs 
compared to tumors based on a quantitative method. The issue may be caused by the 
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intrinsic tissue absorption and fluorescence light scattering effects. More attention is needed 
for the interpretation of LCP NP uptake using fluorescence-labeling dye.
PDT applications involve three major components including photosensitizer, light source 
and tissue oxygen. Photosan, a mixture of porphyrin oligomers, is intracellularly converted 
into the active photosensitizer, protoporphyrin IX (PpIX), in epithelial cells [21]. Reactive 
oxygen species generated can kill tumor cells directly or damage tumor-associated 
vasculature, leading to thrombus formation and subsequent tumor infarction.
For PDT of cancers of the head and neck, photosan is usually administered by intravenous 
injection (2 mg/kg) 48 h before the light treatment (total light dose, 100 J/cm2). A previous 
clinical study demonstrated that 51 of 57 patients with basal cell carcinoma, 6 of 7 patients 
with squamous cell carcinoma of the skin, 6 of 7 patients with oropharyngeal carcinoma, 
and 11 of 12 patients with laryngeal carcinoma showed a complete histologically confirmed 
response to a single course of PDT with systemic administration of photosan over a follow-
up period of 13–71 months [22].
Recent studies have investigated the effects of PDT-induced hypoxia on the expression of 
proangiogenic factors and their relevance to treatment efficacy. Ferrario et al. [23] was the 
first to show that photofrin–PDT induces a modest increase in VEGF levels in BA 
carcinoma cells in vitro. They found that PDT performed on tumors in vivo resulted in 
HIF1α and VEGF upregulation. The results were consistent with Henderson and Donovan 
findings [24] showing that photofrin–PDT stimulates release of PGE2 from macrophages 
and RIF tumor cells in culture and that the extent of release was dose dependent. Our 
experimental strategy was to knock down HIF1α gene expression before conducting PDT on 
OSCC tumors in order to investigate the efficacy of combined therapy.
In general, HIF1α siRNA formulated in LCP reduced HIF1α expression, increased 
apoptosis, inhibited proliferation of tumor cells, and enhanced photosan–PDT reduction in 
tumor volume. After treatment, microvascular CD31 and Ki67 immunostainings were 
significantly lower than in untreated tumors (Fig. 8), consistent with anti-angiogenic and 
anti-proliferative activities of HIF1α siRNA. LCP did not cause changes in host 
physiological profiles based on histopathological observation (Fig. 7). HIF1α siRNA 
formulated in LCP did not show any toxicity at the therapeutic dose, elicit any significant 
immune response (Fig. S4) and no organ toxicity was observed (Figs. S5–S8).
Previous researchers have reported that reactive oxygen species (ROS) play a crucial role in 
the regulation of HIF1α in a variety of cell types [25]. Sasabe et al. [26,27] studied how 
HIF1α influences the regulation of ROS generation and degradation in human OSCC. They 
reported that downregulation of HIF1α increases the intracellular levels of ROS in several 
human OSCC lines. In contrast, ROS production induced by chemotherapy agents was also 
decreased by the HIF1α expression vector transfected into oral squamous carcinoma cells-2 
(OSC-2) and the anticancer agent-generated ROS amount was increased in the HIF1α 
siRNA duplex knockdown in human oral squamous carcinoma cells-5 (OSC-5). In the 
HIF1α knockdown OSCC cells, the expression of P-glycoprotein, heme oxygenase-1, 
manganese-superoxide dismutase and ceruloplasmin were downregulated and the 
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intracellular levels of chemotherapeutic drugs and ROS were sustained at higher levels after 
the treatment with the anticancer agents. Their findings are supportive to our conclusion that 
the downregulation of HIF1α is promoting ROS generation in cancer cells to enhance cell 
apoptosis via photodynamic therapy. Therefore, the combined silencing HIF1α gene therapy 
with photodynamic therapy could enhance PDT therapeutic outcome significantly. It 
suggests more ROS generated by downregulation of HIF1α could enhance ROS-mediated 
PDT therapeutic efficacy.
In summary, IV administered LCP could efficiently target the OSCC tumor to deliver 
therapeutic siRNA without presenting immunological or toxicological problems for the host. 
Systemic administration of HIF1α siRNA by targeted LCP appears to result in safe, stable, 
effective and sequence-specific inhibition of OSCC tumor growth at a relatively low siRNA 
dose (0.36 mg siRNA/kg body weight). Future experiments employing PDT prior to HIF1α 
siRNA in LCP and/or in combination with small-molecule drugs are likely to further 
enhance the antitumor potency of this system. We conclude that HIF1α siRNA formulated in 
LCP combined with PDT has the potential to emerge as an effective treatment for human 
OSCC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Effect of HIF1α siRNA gene therapy on anti-cancer effects of photodynamic therapy in 
cultured human SCC4 cells. Cells were treated with 50 nM HIF1α or scrambled siRNA to 
reduce HIF1α expression (not shown) and then subjected to photodynamic therapy using 0, 
0.5, 1 and 2 μg/ml photosan at 24, 48 and 72 hrs after siRNA treatment. The percentage of 
surviving cells was measured by MTT assay as described and considered an indicator of 
anti-cancer effects of combined therapy. A significant difference (p < 0.001;**) in survival 
rate was seen between HIF1α siRNA/PDT (solid black bars) versus PDT alone (solid white 
bars). A significant difference (p < 0.005;*) in survival rate was seen between HIF1α 
siRNA/PDT (solid black bars) and scrambled siRNA/PDT (gray bars), while no significant 
difference was seen with scrambled siRNA (middle bar) when compared to PDT alone.
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Characterization of LCP nanoparticles. (A) TEM imaging of LCP-HIF1α siRNA-AA was 
performed as described in Materials and Methods. (B) Size distribution of LCP HIF1α 
siRNA nanoparticles was determined as described. (C) Average LCP particle size and zeta 
potential of encapsulated HIF1α siRNA with AA was determined as described.
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In vitro cellular uptake analysis of sigma receptor competition, existence of sigma receptors 
in OSCC cells and effect of anisamide targeting of LCP on sub-cellular distribution of 
delivered dsDNA cargo in cultured SCC4 cells. (A) Sigma receptor binding competition 
analysis of untreated, free DNA, DNA in non-targeted (no anisamide) LCP NP and DNA in 
targeted (with anisamide) LCP NP using haloperidol, the sigma receptor antagonist. (B) 
Western blots on examination of sigma receptor of SCC4 and SAS cell lines. (C, D) Texas 
Red-labeled HIF1α dsDNA was used as a model for siRNA and delivered to SCC4 cells 
using either AA-targeted or untargeted control LCP-PEG in order to investigate the effects 
of nanoparticle targeting on subcellular distribution of delivered cargo. Cells were visualized 
by confocal microscopy 40 minutes after LCP treatment. Nuclei were stained with DAPI 
(blue) and cell membranes were stained with wheat germ agglutinin (green). Arrows 
indicate the location of HIF1α dsDNA (red). (For interpretation of the references to color in 
this figure legend, the reader is referred to the web version of this article.)
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Bio-distribution of HIF1α dsDNA cargo after delivery by targeted LCP nanoparticles. SCC4 
xenograft tumors reached 500–800 mm3 and then mice were either left untreated (left) or 
intravenously injected with 6 μg LCP-Texas red-HIF1α dsDNA. Xenogen IVIS tumor 
imaging was performed 4 hours later as described.
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Effect of HIF1α siRNA delivered by targeted LCP nanoparticles on SCC4 tumor volume 
when combined with photodynamic therapy SCC4 xenograft tumors reached 500–800 mm3 
and then mice were intravenously injected on days 0, 1 and 2 with PBS (○) or 6 μg targeted 
LCP carrying either scrambled siRNA (△) or HIF1α siRNA (□, ■ and ●) followed by 
photosan (△, □ and ●) and light treatment (△, ■ and ●) on day 3. Tumors were measured 
daily as described to determine volume compared to day 0 and then converted to growth rate 
(%). Tumors were removed for pathological examination and q-PCR analysis on day 10.
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Effect of LCP-HIF1α siRNA on HIF1α mRNA levels in SCC4 xenograft tumor tissue. 
SCC4 xenograft tumor-bearing mice were intravenously injected with either PBS alone or 
targeted LCP nanoparticles carrying HIF1α siRNA on days 0, 1, and 2 followed by photosan 
and light treatment on day 3. Real-time quantitative PCR performed on day 10 revealed an 
80% decrease in HIF1α mRNA level in siRNA-treated tumor tissue compared to PBS alone 
or scrambled siRNA (Student t-test, n = 4–8, p < 0.001).
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Hematoxylin and eosin-stained tissue sections from SCC4 xenograft tumor-bearing mice 
after treatment with targeted LCP-HIF1α siRNA. SCC4 xenograft tumors reached 500–800 
mm3 and then mice were intravenously injected on days 0, 1 and 2 with PBS or 6 μg LCP 
carrying either scrambled siRNA or HIF1α siRNA followed by photosan and light treatment 
on day 3. No major changes were observed in LCP-HIF1α siRNA treated liver and kidney 
tissue compared to scrambled siRNA or untreated tissue on day 10 after the start of 
treatment. However, major hollow areas were seen in tumor tissues treated with HIF1α 
siRNA. Bar standards for 100 μm.
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(a) Effect of targeted LCP-HIF1α siRNA on SCC4 xenograft tumor angiogenesis, 
proliferation and apoptosis. SCC4 xenograft tumors reached 500–800 mm3 and then mice 
were intravenously injected on days 0, 1 and 2 with PBS or 6 μg LCP carrying either 
scrambled siRNA or HIF1α siRNA followed by photosan and light treatment on day 3. 
Immunohistochemical staining of tumor sections was then performed as described to 
determine effects on CD31 (brown), Ki67 (brown), caspase-3 (brown) and TUNEL assays 
(yellowish-red). Bar standards for 100 μm. (b) Quantification of the staining intensity of 
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CD31, Ki67 and caspase-3 using image J software in (a). (For interpretation of the 
references to color in this figure legend, the reader is referred to the web version of this 
article.)
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Table 1A
Establishment of SCC4 xenograft mouse models for treatments.
Group Experiments
1 PBS alone every 24 h for 3 days
2 LCP scramble siRNA (mock) every 24 h for 3 days and treated with PDT
3 LCP HIF1α siRNA every 24 hrs for 3 days and treated with photosan without light at the 4th day
4 LCP HIF1α siRNA every 24 hrs for 3 days and treated with PBS with light at the 4th day
5 LCP HIF1α siRNA every 24 hrs for 3 days and treated with PDT at the 4th day
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Table 1B
Establishment of SAS xenograft mouse models for treatments.
Group Experiments
1 PBS alone every 24 h for 3 days
2 LCP scrambled siRNA (mock) every 24 h for 3 days
3 LCP HIF1αsiRNA every 24 hrs for 3 days
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